Aurinia Pharmaceuticals (AUPH) EBIT (2018 - 2025)
Historic EBIT for Aurinia Pharmaceuticals (AUPH) over the last 9 years, with Q3 2025 value amounting to $29.7 million.
- Aurinia Pharmaceuticals' EBIT rose 15319.2% to $29.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.0 million, marking a year-over-year increase of 31413.8%. This contributed to the annual value of -$4.7 million for FY2024, which is 9488.83% up from last year.
- According to the latest figures from Q3 2025, Aurinia Pharmaceuticals' EBIT is $29.7 million, which was up 15319.2% from $20.1 million recorded in Q2 2025.
- Aurinia Pharmaceuticals' EBIT's 5-year high stood at $29.7 million during Q3 2025, with a 5-year trough of -$50.5 million in Q1 2021.
- In the last 5 years, Aurinia Pharmaceuticals' EBIT had a median value of -$16.3 million in 2023 and averaged -$16.7 million.
- As far as peak fluctuations go, Aurinia Pharmaceuticals' EBIT crashed by 8678.12% in 2021, and later soared by 142736.29% in 2025.
- Quarter analysis of 5 years shows Aurinia Pharmaceuticals' EBIT stood at -$32.7 million in 2021, then increased by 14.08% to -$28.1 million in 2022, then fell by 5.6% to -$29.7 million in 2023, then skyrocketed by 94.38% to -$1.7 million in 2024, then soared by 1882.2% to $29.7 million in 2025.
- Its last three reported values are $29.7 million in Q3 2025, $20.1 million for Q2 2025, and $21.8 million during Q1 2025.